Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVRO AVROBIO		$9.98	$0.88 ▼ $1.65	$62.85M	1.23	269,831 shs	206,800 shs
CADL Candel Therapeutics	$4.92 -0.4%	$5.20	$3.79 ▼ $14.60	$246.51M	-0.87	1.47 million shs	874,819 shs
CRDF Cardiff Oncology	$3.02 -18.4%	$3.08	$2.01 ▼ $5.64	$200.91M	1.61	1.19 million shs	3.72 million shs
TVGN Semper Paratus Acquisition	$1.20 -1.6%	$1.15	$0.26 ▼ $3.09	$220.67M	-0.69	5.05 million shs	371,487 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVRO AVROBIO	0.00%	0.00%	0.00%	0.00%	-91.78%
CADL Candel Therapeutics	0.00%	-8.21%	-16.75%	-38.96%	-26.79%
CRDF Cardiff Oncology	0.00%	-20.32%	-1.63%	-19.47%	+20.80%
TVGN Semper Paratus Acquisition	0.00%	-5.51%	+3.45%	+5.26%	+50.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	1.8739 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.8	0.6
CRDF Cardiff Oncology	1.4586 of 5 stars	3.5	0.0	0.0	0.0	2.9	0.0	0.6
TVGN Semper Paratus Acquisition	3.8269 of 5 stars	3.5	4.0	0.0	0.0	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVRO AVROBIO	0.00	N/A	N/A	N/A
CADL Candel Therapeutics	3.00	Buy	$21.00	326.83% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	297.35% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$7.10	491.67% Upside

Current Analyst Ratings Breakdown

Latest AVRO, CADL, CRDF, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/12/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/29/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVRO AVROBIO	N/A	N/A	N/A	N/A	$2.13 per share	N/A
CADL Candel Therapeutics	$120K	2,054.10	N/A	N/A	$1.41 per share	3.49
CRDF Cardiff Oncology	$680K	295.47	N/A	N/A	$1.86 per share	1.62
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVRO AVROBIO	$12.16M	$0.69	2.03	N/A	N/A	N/A	-50.52%	-47.13%	N/A
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest AVRO, CADL, CRDF, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVRO AVROBIO	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVRO AVROBIO	N/A	26.17	26.17
CADL Candel Therapeutics	0.01	4.64	4.64
CRDF Cardiff Oncology	N/A	6.22	6.22
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVRO AVROBIO	62.63%
CADL Candel Therapeutics	13.93%
CRDF Cardiff Oncology	16.29%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
AVRO AVROBIO	9.20%
CADL Candel Therapeutics	16.60%
CRDF Cardiff Oncology	7.70%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVRO AVROBIO	13	44.89 million	40.76 million	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

AVRO, CADL, CRDF, and TVGN Headlines

Recent News About These Companies

Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

June 18 at 9:36 AM | marketbeat.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18 at 8:30 AM | globenewswire.com

Tevogen Bio

June 17 at 11:45 AM | thepharmaletter.com

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral Capital

June 11, 2025 | americanbankingnews.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.com

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.com

Tevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral Capital

June 10, 2025 | marketbeat.com

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of Stock

June 9, 2025 | marketbeat.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short Interest

June 1, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.com

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

May 28, 2025 | marketbeat.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

Tevogen expands target for COVID treatment to seniors

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVRO, CADL, CRDF, and TVGN Company Descriptions

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Candel Therapeutics NASDAQ:CADL

$4.92 -0.02 (-0.40%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.12 (+2.34%)

As of 06/18/2025 07:57 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$3.02 -0.68 (-18.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.05 +0.03 (+0.99%)

As of 06/18/2025 07:55 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Semper Paratus Acquisition NASDAQ:TVGN

$1.20 -0.02 (-1.64%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.08%)

As of 06/18/2025 06:44 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time